TP53 and ovarian carcinoma: We think that lack of clinical associations of ERBB2 overexpression in ovarian cancer studies may be due to (1) small group sizes (Table 1); (2) no regard to TP53 status and (3) overly restrictive criteria of ERBB2 overexpression.